Antibodies to fibroblast growth factor (FGF23)

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S387100, C530S387900, C530S388100, C530S388240

Reexamination Certificate

active

07314618

ABSTRACT:
The present invention relates to antibodies that bind to FGF23 polypeptides and to FGF23 mutant polypeptides.

REFERENCES:
patent: 5693775 (1997-12-01), Nathans et al.
patent: 2002/0082205 (2002-06-01), Itoh et al.
patent: WO94/17810 (1994-08-01), None
patent: WO94/23744 (1994-10-01), None
Bainchine et al. 1971, Birth Defects Orig. Aric. Ser., 7:287-295.
Bonaventure et al. 1994, Exp. Cell Res., 212:97-104.
Carthew 2001, Curr. Opin. Cell Biol., 13:244-248.
Cranage et al. 1986, EMBO J. 5:3057-3063.
Econs et al. 1997, J. Clin. Endocrinol. Metab. 82:674-681.
Econs et. al. 1994, Bone and Min., 24:17-24.
Elbashir et al. 2001, Nature, 411:494-498.
Haselhoff et al. 1988, Nature 334:585-591.
Kay et al. 1997, Proc. Natl. Acad. Sci. U.S.A. 94:12744-12746.
Nagy and Rossant (1993, In: Gene Targeting, A Practical Approach, pp. 146-179, Joyner ed., IRL Press).
Rowe, et al. 1991, Hum. Genet. 89:539-542.
Tanner et al., IN: Antisense Research and Applications, CRC Press INC. 1993, pp. 415-426.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antibodies to fibroblast growth factor (FGF23) does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to fibroblast growth factor (FGF23), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to fibroblast growth factor (FGF23) will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3962915

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.